Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD

2021232 citationsJournal Articlebronze Open Access

Authors

Glenn M. Chertow · Indiana University – Purdue University Indianapolis

Pablo E. Pérgola · Renal Associates P. A.

Youssef M.K. Farag · Indiana University – Purdue University Indianapolis

Rajiv Agarwal · Indiana University School of Medicine

Susan Arnold · Baylor University Medical Center

Gabriel Bako · University of Oradea

Geoffrey A. Block

Abstract

Vadadustat, as compared with darbepoetin alfa, met the prespecified noninferiority criterion for hematologic efficacy but not the prespecified noninferiority criterion for cardiovascular safety in patients with NDD-CKD. (Funded by Akebia Therapeutics and Otsuka Pharmaceutical; PRO<sub>2</sub>TECT ClinicalTrials.gov numbers, NCT02648347 and NCT02680574.).

Topics & Keywords

Erythropoietin and Anemia Treatment Dialysis and Renal Disease Management Chronic Kidney Disease and Diabetes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 384, Issue 17, pp. 1589-1600

DOI: 10.1056/nejmoa2035938

Field-Weighted Citation Impact: 25.72